Fig. 3. The mean change in (A) BCVA and (B) central macular thickness (CMT) from baseline to 12 months for all patients with treat-and-extend regimen using aflibercept for exudative age-related macular degeneration. BCVA = best-corrected visual acuity; logMAR = logarithm of the minimum angle of resolution. *p < 0.05.

J Retin 2021;6:99-109 https://doi.org/10.21561/jor.2021.6.2.99

© 2021 J Retin